⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217208 | 0.82 | ALDH1A1 (0.73) | — | |
| SCHEMBL19788625 | 0.82 | ALDH1A1 (0.73) | — | |
| SCHEMBL7217205 | 0.82 | ALDH1A1 (0.73) | — | |
| SCHEMBL28477151 | 0.81 | — | — | |
| SCHEMBL10937525 | 0.80 | ALDH1A1 (0.71) | — | |
| SCHEMBL15228335 | 0.80 | ALDH1A1 (0.71) | — | |
| SCHEMBL6250744 | 0.79 | ALOX15 (0.41) | — | |
| SCHEMBL1871028 | 0.79 | ALDH1A1 (0.65) | — | |
| SCHEMBL113776 | 0.79 | — | — | |
| SCHEMBL6913629 | 0.79 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| US-20210070775-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | US | disclosed |
| WO-2021043951-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | WO | disclosed |
| CN-111770928-A | Synthesis of oligonucleotides and nucleic acids | 埃万奈蒂克有限公司 | 2020-10-13 | — | — | CN | disclosed |
| EP-3615544-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2020-03-04 | — | — | EP | disclosed |
| US-10538535-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2020-01-21 | — | — | US | disclosed |
| US-10442820-B2 | — | — | 2019-10-15 | — | — | US | disclosed |
| US-20180312529-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | US | disclosed |
| WO-2018197663-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | WO | disclosed |
| CN-107033164-A | Prepare the synthetic method of ecteinascidin compounds | 法马马有限公司 | 2017-08-11 | — | — | CN | disclosed |
| CN-103038240-A | Synthetic method for preparing ecteinascidin compounds | PHARMA MAR SA | 2013-04-10 | — | — | CN | disclosed |